Relaxing Immersive Virtual Reality Interventions Acceptable, Feasible
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 17, 2023 -- Relaxing immersive virtual reality (VR) interventions are acceptable and feasible and can offer benefits to patients with cancer, according to a review published online Oct. 16 in BMJ Supportive & Palliative Care.
William R.G. McGhee, from Queen's University in Belfast, and colleagues conducted a systematic review of the literature to examine immersive VR in adult populations with chronic physical illness to examine the impact on psychological well-being. A total of 31 studies met the inclusion criteria.
The researchers found that among adults with cancer, dementia, cardiovascular disease, kidney disease, and multiple sclerosis, relaxing and engaging immersive VR interventions were shown to be acceptable and feasible. The evidence about effectiveness was more limited because many of the studies reviewed were feasibility or pilot studies. Immersive VR was suggested to have a positive effect on anticipatory anxiety symptoms and pain, based on evidence mainly from patients with cancer.
"Our findings suggest that VR interventions are acceptable treatments that have the potential to improve physical and psychological consequences of physical illness," the authors write. "There is good-quality research to suggest that these VR interventions are effective in reducing pain and distress, particularly among people with cancer."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
American Society of Clinical Oncology, May 30-June 4
The annual meeting of the American Society of Clinical Oncology was held from May 30 to June 4 in Chicago and hosted more than 34,000 participants from around the world, including...
New Clinical Score Can Predict Immune Checkpoint Blockade Response
MONDAY, June 10, 2024 -- For patients with cancer, a novel clinical score using a six-feature regression model can predict immune checkpoint blockade (ICB) response probability...
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.